<div>
  <p>
  </p>
  <ul>
    <li>
      <p>
        Genetic testing and CDx tools company Guardant Health has teamed up with Cancer Research UK and its innovation unit, Cancer Research Horizons, to mainly focus on clinical trials run by CRUK's Centre for Drug Development, comprising the DETERMINE trial, reportedly the first national precision medicine trial in the UK targeting rare cancers.
      </p>
    </li>
    <li>
      <p>
        Under the partnership, the parties may also share data and samples from the CRUK-funded research network to support the development and validation of Guardant&rsquo;s liquid biopsy and tissue sequencing technologies and other projects.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.labpulse.com/business-insights/trends-and-finance/collaboration/article/15659613/guardant-health-cancer-research-uk-to-partner-on-data-and-research">
      Labpulse.com
    </a>
  </p>
  <p>
  </p>
</div>


Precision Medicine

PROMINENT_CATEGORY

<div>
 
 <p>Genetic testing and CDx tools company Guardant Health has partnered with Cancer Research UK and its innovation unit, Cancer Research Horizons. The focus of the collaboration is on clinical trials conducted by CRUK's Centre for Drug Development, with a specific emphasis on the DETERMINE trial. This trial is reportedly the UK's first national precision medicine trial targeting rare cancers. The partnership will also involve the sharing of data and samples from the CRUK-funded research network. The aim is to support the development and validation of Guardant’s liquid biopsy and tissue sequencing technologies, as well as other projects.</p>
 
</div>

Guardant Health partners with Cancer Research UK to focus on DETERMINE trial targeting rare cancers

DISRUPTOR_PRESENT

<div>
 <ul>
  <li><p>Genetic testing and CDx tools company Guardant Health and clinical trial technology company Flatiron Health, integrates Guardant's genomic profiling tests within Flatiron's OncoEMR, a cloud-based electronic medical record (EMR) tool.</p></li>
  <li><p>The integration simplifies access to critical data for over 2,000 clinicians in the Flatiron network, which includes more than 800 cancer care locations across the US.</p></li>
  <li><p>Users can submit Guardant Health test orders, track updates, and receive test results directly in the patient record via the Molecular Profiling Integration on the OncoEMR platform, streamlining workflows for physicians and saving time in the ordering process.</p></li>
 </ul>
</div>

Guardant Health integrates genomic profiling tests within Flatiron’s OncoEMR to simplify access to critical data

All Updates

Guardant Health partners with Cancer Research UK to focus on DETERMINE trial targeting rare cancers

Guardant Health integrates genomic profiling tests within Flatiron’s OncoEMR to simplify access to critical data

Guardant Health beats analyst consensus in Q2 2023; revises 2023 guidance

Blue Cross and Blue Shield of Louisiana covers Guardant’s blood test for cancer residual disease

Guardant Health to raise USD 350 million in upsized offering

Guardant Health reports strong revenue growth in Q1 2023 as precision oncology revenue rises

Guardant Health receives Medicare coverage for Guardant360 Response test

Guardant Health in line with analysis consensus; reports growth in revenue in Q4 2022 and full year

Precision medicine startups announce preliminary earnings for 2022

Guardant Health misses analysis consensus; reports growth in revenue in Q3 2022